This phase 1b trial (NCT02670044) evaluated venetoclax-idasanutlin in patients with
relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia
(AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly …

PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …

Simple Summary The use of venetoclax combined with hypomethylating agents or low-dose
cytarabine in patients with newly diagnosed acute myeloid leukemia unfit for intensive …

We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly
selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with …

Venetoclax in combination with intensive therapies is explored in both the upfront and
relapse/refractory (R/R) setting, and available data suggest that such regimens are effective …

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally
poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently …

Venetoclax‐azacitidine is approved for treatment of patients with newly diagnosed acute
myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall …

Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients.
Venetoclax was available prior to approval off-label. We assessed our single-institution off …